Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02089763 is registered in ClinicalTrials.gov with Bio-Cancer Treatment International Limited as lead sponsor.

NCT NCT02089763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02089763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Bio-Cancer Treatment International Limited
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
March 31, 2017
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma